Cardogrel

Selected form

Clopidogrel

Method of action: Antiplatelet, Antithrombotic

Treatment option: Coronary Artery Bypass Graft, Peripheral Arterial Disease, Cerebrovascular Accident, Accelerating Angina, Acute Coronary Syndrome, Heart Attack, Angina Pectoris

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardogrel

Quick Facts

Property	Description
Active ingredient	Clopidogrel Bisulfate
Form	Film-coated tablet
Pharmacological class	Antiplatelet agent (Antiaggregant drug)
Common use	Thrombotic event prevention
Origin	Synthetic compound (Thienopyridine derivative)

What Type of Medicine is Cardogrel?

Cardogrel is a prescription-only medicine whose active composition is the internationally recognized substance Clopidogrel Bisulfate, classified as a highly specific Antiplatelet agent (Antiaggregant drug). This synthetic compound belongs chemically to the Thienopyridine derivatives, a class of drugs clinically recognized for their specialized action in reducing the propensity of blood to clot. As an Antiplatelet agent, its primary function is influencing blood flow dynamics. This Thienopyridine derivative is central to its role in cardiovascular medicine.

Composition and Physical Form of Cardogrel

The active substance in this single-ingredient product is Clopidogrel (as the Bisulfate salt), and it is delivered as an oral preparation in the physical form of a film-coated tablet. Cardogrel is administered via the oral route, ensuring convenience for long-term use in adults. The chemical substance Clopidogrel is technically known as a prodrug, a feature that differentiates it from medicines that are immediately active upon ingestion. This property means it requires metabolic transformation within the body after consumption to become fully effective and achieve selective and irreversible P2Y12 receptor blockade.

General Purpose: Why is Cardogrel Used?

The general purpose of this Antiplatelet agent is to achieve thrombotic event prevention by maintaining effective platelet aggregation inhibition within the blood vessels. For instance, it is typically used in a scenario where an individual requires a sustained reduction in clotting risk. The primary benefit of Cardogrel is to reduce the formation of unwanted clots, which can disrupt circulation. Its entire therapeutic identity is defined by its sustained ability to perform this essential function, promoting smoother blood flow in the cardiovascular system.

Regulatory References

NIH StatPearls: Clopidogrel

What side effects are possible with Cardogrel?

Cardogrel: Possible Side Effects and Safety Information

This information details the officially documented adverse reactions and safety constraints for Cardogrel, based strictly on governmental regulatory documents.

Adverse Reaction Scope

The most significant risk associated with Cardogrel is bleeding, which can range in frequency and severity. Side effects are formally classified by frequency and the body system they affect (System-Organ Class or SOC).

Frequency Classification	Examples of Documented Side Effects
Common (ge 1/100)	Headache, Dyspepsia, Diarrhea, Non-serious bleeding (e.g., bruising, epistaxis).
Uncommon (ge 1/1,000)	Dizziness, Rash, Gastritis.

Serious Adverse Reactions (SARs), while typically Rare (ge 1/10,000) or Very Rare (< 1/10,000), include potentially life-threatening events that are highlighted in regulatory labeling:

Severe Bleeding Events: Including intracranial hemorrhage and major gastrointestinal bleeding.
Thrombotic Thrombocytopenic Purpura (TTP): A rare, critical blood disorder; the risk is highest during the first two weeks of therapy.
Severe hypersensitivity reactions.

Safety Restrictions and Limitations

Contraindications define situations where the drug must not be used, as explicitly stated in the prescribing information:

Active pathological bleeding (e.g., peptic ulcer).
Severe hepatic impairment (severe liver disease).

Population-Specific Safety Notes: Use is not recommended during pregnancy unless clearly necessary. Caution is required when prescribing to patients with severe renal impairment.

This structure ensures patients are informed of both common, expected effects and rare, critical risks, while defining the mandatory limits for safe use.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Cardogrel, whose active substance is Clopidogrel, is officially documented to result from an excessive antiplatelet effect. The recognized clinical manifestations of overexposure include signs of unusual bruising or bleeding and an officially documented prolonged bleeding time, leading to subsequent bleeding complications or hemorrhage.

Official regulatory guidance mandates that immediate action be taken when signs of overexposure are noted. Urgent medical help must be sought if any severe outcomes or systemic signs are observed. Contact emergency services immediately if the person has experienced collapse, a seizure, trouble breathing, or cannot be awakened. The regulatory instruction is to seek immediate medical attention or to call the poison control helpline.

The management of severe overexposure is defined as symptomatic and supportive treatment. It is officially stated that no specific pharmacological antidote is known for Cardogrel overdose. However, regulatory documents describe that appropriate therapy should be considered if bleedings are observed, and platelet transfusion may be considered, based on biological plausibility, as a measure to help restore clotting ability. Population-specific overdose risks are not explicitly detailed in the dedicated official labeling.

Therapeutic Uses of Cardogrel

What Cardogrel Treats: Main Uses and Benefits

Preventing Recurrent Heart Attack and Ischemic Stroke

Cardogrel is commonly used for secondary prevention in adults who have recently experienced a heart attack (myocardial infarction) or ischemic stroke. The core therapeutic benefit is that it may contribute to easing the risk of subsequent acute episodes, and contributes to improved comfort during difficult periods. It is also applied when appropriate for sustained risk management in managing acute symptomatic episodes, such as unstable angina and other forms of Acute Coronary Syndrome. The medication is commonly used to help with conditions characterized by acute or episodic changes, such as recent heart attack, recent ischemic stroke, and established Peripheral Arterial Disease (PAD).

Sustaining Vascular Flow in High-Risk Contexts

The medication is commonly used for continuous management in patients with chronic conditions like established Peripheral Arterial Disease (PAD). In this context, it is commonly used to help with conditions characterized by periods of heightened symptoms associated with chronic vascular disease. Furthermore, Cardogrel is commonly used for patients who have undergone coronary stenting procedures, where it may assist with symptoms that interfere with daily functioning by being applied in addressing the potential for blood flow disruption at the intervention site. It is considered relevant in contexts involving heightened systemic burden to maintain blood flow and supports general well-being during symptomatic phases.

Quick Fact: Relief for Vascular Stress
Primary Goal	May assist with maintaining functional stability in high-risk vascular scenarios.
Target Conditions	Recent Myocardial Infarction, Ischemic Stroke, and post-stent procedures.
Therapeutic Role	Applied in contexts involving heightened systemic burden to ease the risk of acute, recurrent episodes.

Regulatory References

European Medicines Agency (EMA) product information

Eligibility and Restrictions for Use

Who Can and Cannot Use Cardogrel?

Cardogrel (Clopidogrel) is officially approved for use in the adult population only, specifically for individuals with conditions like recent Myocardial Infarction, Ischemic Stroke, or Peripheral Arterial Disease. For the pediatric population (children and adolescents), use is generally not recommended as efficacy and safety have not been established in this age group.

Absolute Contraindications (Must Not Use)

According to regulatory documents, Cardogrel is contraindicated and must not be used by patients with:

Active pathological bleeding, such as an active peptic ulcer or intracranial hemorrhage.
Severe hepatic impairment (severe liver disease).
Known hypersensitivity to clopidogrel or any component of the formulation.

Populations Requiring Caution or Restriction

Use of Cardogrel requires caution and is restricted in patients with renal impairment or moderate hepatic impairment due to limited clinical experience. For pregnant women, use is not recommended as a precautionary measure due to a lack of human data. Patients who are CYP2C19 poor metabolizers may have diminished antiplatelet activity, and the optimal dose regimen for this group is not established.

What should I know about interactions with other medicines?

Cardogrel Interactions with other medicines and products

Official regulatory information for Cardogrel (Clopidogrel) identifies several documented interactions that structure its co-administration profile, primarily related to metabolism and bleeding risk.

Formal Co-Administration Restrictions

Classification	Interacting Product Category	Regulatory Constraint
Avoid Concomitant Use	Strong CYP2C19 Inhibitors (e.g., Omeprazole, Esomeprazole)	Reduces Cardogrel's antiplatelet activity; not prevented by dose spacing.
Not Recommended	Oral Anticoagulants (e.g., Warfarin)	May increase the intensity of bleedings due to independent effects on hemostasis.
Contraindicated	Abrocitinib	Prohibited during the initial three months of Abrocitinib therapy.

Documented Interaction Mechanisms and Effects

Combining Cardogrel with other antiplatelet agents or substances that affect bleeding, such as NSAIDs and Heparin, carries an officially noted increased risk of bleeding due to additive pharmacodynamic effects.

Cardogrel's metabolite is documented as a strong CYP2C8 inhibitor, resulting in increased systemic exposure to certain co-administered medicines, such as Repaglinide. Additionally, Opioid Agonists (e.g., Morphine) may delay and reduce the absorption of Cardogrel, resulting in lower exposure to its active metabolite. Herbal products such as Ginkgo Biloba are associated with increased bleeding risk.

As a procedural constraint, discontinuation of Cardogrel is typically required 5 to 7 days prior to elective surgery associated with a major risk of bleeding.

Mechanism of Action

Metabolism-Dependent P2Y12 Receptor Blockade

Cardogrel (Clopidogrel) functions as an inactive prodrug and requires conversion by specific liver enzymes, primarily CYP2C19, into its biologically active metabolite. This active metabolite then acts as a selective antagonist, forming a permanent, covalent bond with the P2Y12 receptor on the surface of blood platelets. This irreversible blockade prevents the receptor's natural activator, ADP (adenosine diphosphate), from binding and initiating the signaling sequence.

Intracellular Signaling and Antiaggregation Cascade

Blocking the P2Y12 receptor modulates intracellular signaling by preventing the standard mechanism that inhibits adenylate cyclase. This allows the concentration of the internal messenger cyclic AMP ( cAMP) to rise, which leads to the suppression of downstream signals required for platelet activation. This cascade ultimately suppresses the final common pathway for platelet sticking (the GPIIb/IIIa receptor complex), resulting in a sustained inhibition of aggregation capacity across the platelet population.

Mechanism Constraints and Platelet Turnover

The irreversible binding to the P2Y12 receptor ensures the antiplatelet effect is sustained for the entire lifespan of the treated platelet (sim 7-10 days). However, the effect is gradually countered by the continuous production and release of new, unexposed platelets by the body. Furthermore, reliance on CYP2C19 creates a mechanistic limitation, as genetic differences in this enzyme can lead to less efficient conversion of the prodrug, modulating the degree of antiplatelet activity.

Dosage and Administration Information

How Cardogrel is Used: Administration Guidelines

Cardogrel (clopidogrel bisulfate) is administered via the oral route as a film-coated tablet. The usage protocols center on standardized dosing patterns and specific contextual requirements.

Standard Dosing and Administration

Instruction	Detail
Route of Administration	Oral.
Maintenance Dose	75 mg once daily is the standard for long-term use in all approved indications, including recent heart attack (MI), recent stroke, and established Peripheral Arterial Disease (PAD).
Loading Dose Protocol	For Acute Coronary Syndrome (ACS), a single oral 300 mg loading dose is typically given to rapidly establish the antiplatelet effect, followed by the maintenance dose.
Timing with Meals	Cardogrel may be administered with or without food.

Use Patterns and Contextual Rules

Usage involves a once-daily schedule, which is often continued long-term for secondary prevention. For specific acute conditions, such as Non-ST-Elevation ACS, the medicine is administered in combination with low-dose aspirin and may be continued for up to 12 months.

Age-Specific Rule: For medically treated patients over 75 years of age with certain severe heart events (STEMI), the 300 mg loading dose is omitted.

Missed Dose Rule: Adherence to timing is managed by a specific rule: if a dose is missed by less than 12 hours, it should be taken immediately. If more than 12 hours have passed, the missed dose must be skipped, and the regular schedule resumed the next day; two doses must not be taken together.

Recent Clinical Evidence

Evidence for Use in Chronic Vascular Event Prevention

Major research has explored the use of Cardogrel as a single treatment in populations with a history of a vascular event, such as a heart attack or stroke, or in those with Established Peripheral Arterial Disease (PAD). These long-term Randomized Controlled Trials (RCTs) were designed to track patients over periods of several years. The primary outcomes monitored were defined as the incidence of a Major Vascular Event, which includes stroke, heart attack, and vascular death. Some trials described patterns observed in the rate of these events when evaluating the agent in comparison to the control treatment.

Uncertainty exists regarding the variability in patient response, as studies suggest some people exhibit variability in their measured response to the agent. Additionally, the evidence landscape includes discussion regarding the need for an identical, fully published, independent RCT to further characterize the findings of the original major trial.

Evidence for Use in Acute Coronary Syndrome and Post-Stenting

The evidence in this area includes numerous RCTs that evaluated the agent in combination with aspirin (Dual Antiplatelet Therapy, or DAPT) for patients presenting with Acute Coronary Syndrome (ACS) and those who have undergone Coronary Stenting procedures. These studies monitored short-term (30 days) and intermediate-term (6-12 months) outcomes.

The study outcomes examined included the rate of Stent Thrombosis (clotting at the stent site) and subsequent heart attacks. The combined use with aspirin was evaluated in trials that measured the frequency of Major Adverse Cardiac and Cerebrovascular Events observed during the study period. A key area of ongoing research is the optimal duration of this combined therapy.

Research Gaps and Study Limitations

Cardogrel was evaluated in trials that included long-term follow-up durations ranging from two to over five years, providing context for maintenance therapy. However, these long-term outcomes are not fully established for every possible clinical scenario. Studies have explored use in specific patient groups, such as those with Chronic Kidney Disease, but results apply only to the populations studied. Data for other groups, such as children, remain insufficient and evidence is limited. Comparative evidence is lacking in some important clinical situations, meaning definitive conclusions about relative performance are not available.

Frequently Asked Questions (FAQ)

Common questions about Cardogrel (FAQ)

Q: How quickly does Cardogrel start working to prevent clots?

Studies show that the antiplatelet effect of Cardogrel can begin within two hours after taking a single oral dose. However, the maximum effect of the medicine is typically reached after three to seven days of regular use. A loading dose protocol is used in certain acute situations to rapidly establish the medicine's antiplatelet effects, as indicated in official prescribing information.

Q: Is it normal to feel a bit dizzy when first starting Cardogrel?

Dizziness is listed in official regulatory documents as an uncommon side effect of Cardogrel. If you experience dizziness, particularly if it is severe, official guidance suggests this symptom should be discussed with a healthcare provider.

Q: Does Cardogrel interact with common heartburn medications?

Official information states that co-administration with omeprazole and esomeprazole is generally discouraged because these medicines can significantly reduce the antiplatelet effect of Cardogrel. However, other acid-reducing medicines, like common antacids or H2 blockers, generally do not appear to interfere with its anti-clotting activity.

Q: Does Cardogrel affect liver function over time?

Cardogrel is contraindicated (should not be used) in patients who have severe hepatic impairment (severe liver disease). Serious adverse effects related to the liver have been reported rarely. Signs like jaundice (yellowing of the skin or eyes) are highlighted in official documents as requiring urgent consultation with a healthcare professional.

Q: What happens if I forget to take Cardogrel for one day?

Official missed dose rules instruct the patient to take the missed dose immediately if it is less than 12 hours late. If more than 12 hours have passed, the guidance is to skip the missed dose and resume the regular schedule. Regulatory information advises against taking two doses at the same time. Since this medicine is for thrombotic event prevention, any interruption in therapy is associated with a potential increase in the risk of events like heart attack or stroke.

Q: Can Cardogrel cause stomach upset or digestive issues?

Yes, common digestive side effects listed in regulatory documents include indigestion (dyspepsia) and diarrhea. If signs of internal bleeding, such as black, tarry stools, are observed, regulatory information advises seeking urgent medical attention.

Q: Does taking Cardogrel impact the risk of iron deficiency?

The primary safety concern with Cardogrel is an increased risk of bleeding, including bleeding in the gastrointestinal tract. Persistent blood loss can eventually lead to low red blood cell counts, known as anemia. Regulatory documents suggest that appropriate testing should be considered if clinical symptoms related to blood loss or low red blood cell counts are suspected.

Q: Will I need regular blood tests while taking Cardogrel?

Official guidance suggests that blood cell count checks or other relevant testing should be promptly considered if signs of unusual bleeding or blood disorders are suspected. Genetic tests are also available to identify individuals who may not metabolize the drug effectively, as the medicine's conversion process varies among people.

Q: Are headaches a known side effect of Cardogrel?

Yes, headache is listed in regulatory documents as a common side effect of Cardogrel. It is one of the more frequently observed, non-serious effects reported.

Q: What's the difference between a P2Y12 inhibitor and other antiplatelet drugs?

Cardogrel is classified as a P2Y12 inhibitor, which is a specific type of antiplatelet drug. This means its mechanism involves targeting and blocking the P2Y12 receptor on the surface of blood platelets. Other antiplatelet drugs, such as aspirin, prevent clotting by acting on different biological pathways.

Q: Can people with kidney problems take Cardogrel?

Cardogrel is used with caution in patients with kidney problems. The prescribing information notes that caution is required, and use is not recommended in cases of severe renal impairment (severe kidney problems) due to limited clinical experience in this patient group.

Q: Is Cardogrel used in emergency heart situations?

Yes, Cardogrel is indicated for patients with Acute Coronary Syndrome (ACS), which includes severe conditions like unstable angina or heart attack. For these indications, official protocols include a loading dose to rapidly establish the intended antiplatelet effects.

Q: What are the signs of a serious bleeding side effect from Cardogrel?

Serious bleeding can be life-threatening. Signs listed in regulatory documents include unexpected or prolonged bleeding, severe headaches, vomiting blood that looks like coffee grounds, or passing black, tarry stools. If any signs of serious bleeding are observed, immediate medical assistance is necessary.

Q: Is Cardogrel used to prevent strokes as well as heart attacks?

Yes, Cardogrel is officially indicated to reduce the rate of serious events, including future heart attacks and future strokes, in patients who have a history of a recent event or established peripheral arterial disease.

Q: Why do some people experience unexplained rashes while taking Cardogrel?

Rash is listed in official documents as an uncommon side effect of Cardogrel. It is important to be aware that severe hypersensitivity reactions, indicated by a widespread rash or facial swelling, are highlighted in official documents as requiring urgent medical attention.

Q: Can younger adults be prescribed Cardogrel?

Cardogrel is officially approved and indicated for use only in the adult population (age 18 and older). Regulatory documents confirm that its use is not recommended for children or adolescents, as efficacy and safety have not been established in these age groups.

Q: Are there specific genetic factors that affect how Cardogrel works?

Yes, genetic variations in the liver enzyme CYP2C19 can affect how efficiently the drug is converted into its active form. Official warnings note that individuals identified as 'poor metabolizers' may have a reduced antiplatelet effect, and an alternative treatment may be considered by a healthcare provider.

Q: Can Cardogrel be taken during pregnancy or breastfeeding?

Official information states that use during pregnancy is not recommended unless clearly necessary due to limited human data. Small amounts of the medicine and its metabolites are known to be excreted into breast milk. Official prescribing information advises that a healthcare professional must evaluate the risk-benefit profile for the patient.

Q: What are the rare but serious side effects of Cardogrel?

Regulatory labeling highlights several rare but critical adverse reactions. These include severe internal bleeding (such as bleeding in the brain or stomach), a critical blood disorder called Thrombotic Thrombocytopenic Purpura (TTP), and severe allergic reactions. These require immediate medical attention.

How should Cardogrel be stored and disposed of?

How to Store and Dispose of Cardogrel (Clopidogrel)

The storage and disposal of Cardogrel must adhere strictly to official regulatory requirements to maintain its stability and ensure safety.

Storage Conditions

Cardogrel must be stored at controlled room temperature, maintaining conditions below 30 C. The medication must be kept in its original package and the container must be tightly closed to protect it from excess heat, moisture, and light. To prevent accidental ingestion, the tablets must always be stored out of the sight and reach of children. If supplied in an HDPE bottle, the product has a labeled in-use shelf life of 6 months after opening.

Disposal Requirements

Expired or unused Cardogrel must be disposed of at an authorised waste collection point. Official instructions emphasize that the product must not be released to drains or waterways due to potential environmental hazards, and it should not be discarded in general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.